Patient experience CSL is committed to enhancing the patient experience in drug development by: • integrating patient insights and lived experience into patient‑informed clinical development programs, throughout the asset lifecycle; • implementing enrolment strategies to ensure clinical trial populations appropriately reflect the epidemiology of the disease under study; and • ensuring development programs are designed with, not just for, the patients we serve. Co-designing clinical trials with patients Patients bring critical insights as experts in their own conditions. By partnering with patients and their support communities, and actively listening to their lived experiences, CSL is better able to reflect their needs and priorities in the development and delivery of our medicines. We gather patient insights to understand unmet medical needs, the lived experience of disease, feedback on clinical trials, and interactions with the healthcare system. These insights inform more patient-centred trial design and help improve relevance, participation and outcomes. Flexible and accessible trial options CSL incorporates flexible and decentralised options into clinical trial design to improve accessibility, reduce participant burden and promote equity. These options include electronic Clinical Outcome Assessments (eCOA) with Bring Your Own Device capability, eLearning, alternative locations for study procedures, and telehealth visits. These features are designed to make participation easier and more inclusive, supporting improved recruitment and retention while enabling the collection of more robust and representative data. In FY2026, 100% of Phase II/III studies included flexible options, which were recommended by patient advisors to reduce the burden on participants. Patient representation in clinical trials CSL develops Patient Representation Plans for all Phase III and pivotal trials to ensure that the participants in CSL’s clinical studies accurately reflect the real-world population of people living with the conditions being studied. By incorporating insights on disease epidemiology and addressing barriers to participation, CSL aims to improve access to clinical trials and uphold scientific integrity. This contributes to the development of treatments that are safe and effective for broader patient populations. Key initiatives include the following: • Expanding trial sites across remote, regional and diverse urban communities. • Collaborating with patient organisations and advocacy groups to improve access and education. • Embedding flexible trial options to support participation. Industry collaboration and leadership CSL actively collaborates with industry, academic and patient advocacy organisations to advance patient-focused drug development and improve clinical trial practices. CSL holds leadership roles in global initiatives, including: • PALADIN (Patient Advocacy Leaders and Drug Development Industry Network); and • DTRA (Decentralized Trials & Research Alliance). CSL also contributes to Tufts Centre for the Study of Drug Development (CSDD) working groups to share insights and develop industry benchmarks that enhance trial performance and efficiency. CSL partners with patient-led organisations, including: • SCDAA (Sickle Cell Disease Association of America) C.A.R.E.S. Consortium; and • EUPATI (European Patient Academy on Therapeutic Innovation). Through these collaborations, we help advance best practices in patient-informed drug development and strengthen the integration of patient perspectives across the research and product development lifecycle. Progress on CSL’s Patient experience commitment Progress Focus area Commitment by FY2030 FY2026* FY2025 Patient insights Informed product development: All of CSL’s therapeutic product development programs are informed by patient insights. 100%1 100% Representative clinical trials Representative clinical trials: Phase III clinical trials incorporate participants that are representative of the target indicated population. 100%2 100% 1. C urrently, 100% of Phase II/III clinical trials include patient insights. Those insights have contributed to the inclusion of flexible participation options in study designs in 100% of therapy and vaccine trials in FY2026. CSL is working to expand patient insights into all stages of the development process. 2. 1 00% of Phase III and pivotal clinical trials include Patient Representation Plans. * Limited assurance by Deloitte. 31 CSL Limited Annual Report 2025/26
RkJQdWJsaXNoZXIy MjE2NDg3